Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pari-flo is a multi-component botanical product developed by Grand Medical Group for the management of urological disorders, specifically chronic prostatitis and benign prostatic hyperplasia (BPH). The formulation is composed of several plant extracts, including *Serenoa repens* (Saw Palmetto), *Urtica dioica* (Nettle), and *Cucurbita pepo* (Pumpkin seed), which are traditionally used for their anti-inflammatory, anti-androgenic, and decongestant properties. Preclinical research conducted by the sponsor has utilized rat models to demonstrate its efficacy in reducing prostatic inflammation and improving urinary flow. While marketed as a nutraceutical or phytopreparation in certain regions, it remains in the preclinical research phase for broader clinical validation according to company pipeline disclosures.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pari-flo.